🧬 TESAMORELIN: POPULATION MATTERS
A research headline can sound broad until you look at who was actually studied.
2026 meta-analyses examined randomized trials of tesamorelin in people living with HIV who had HIV-associated lipodystrophy. Researchers evaluated outcomes including visceral adipose tissue, body composition, hepatic fat, metabolic measures, and safety.
That’s meaningful human research, but it shouldn’t be casually generalized into a claim about weight loss for everyone.
The population, indication, study design, and endpoints all matter.
That’s why we always read past the headline. 🧬